Výsledky vyhledávání - "Sander J H, van Deventer"

Akademický článek

Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents

Autor: Jason G. van Genderen, Malon Van den Hof, Claudia G. de Boer, Hans P. G. Jansen, Sander J. H. van Deventer, Sotirios Tsimikas, Joseph L. Witztum, John J. P. Kastelein, Dasja Pajkrt

Publikováno v: Viruses, Vol 13, Iss 10, p 2067 (2021)

HIV is an independent risk factor of cardiovascular disease (CVD); therefore, perinatally HIV-infected (PHIV) children potentially have a greater CVD risk at older age. Lipoprotein(a) (Lp(a)) is an established risk factor for CVD in the general popul

Externí odkaz: https://doaj.org/article/e7fc141841c847bf85d41fbf0d24e115

Zobrazit plný text záznamu

How large pharma impacts biotechnology startup success

Autor: Gina Melchner von Dydiowa, Sander J. H. van Deventer, Daniela S. Couto

Publikováno v: Nature Biotechnology. 39:266-269

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::042f38ef6f35e0ddc8f88e0a8cea6f17
https://doi.org/10.1038/s41587-021-00821-x

Zobrazit plný text záznamu

Longitudinal assessment of lipoprotein(A) levels in perinatally HIV-infected children and adolescents

Autor: Sotirios Tsimikas, Claudia G. de Boer, John J.P. Kastelein, Sander J. H. van Deventer, Hans Jansen, Jason G. van Genderen, Dasja Pajkrt, Malon Van den Hof, Joseph L. Witztum

Publikováno v: Viruses, vol 13, iss 10
Viruses
Viruses, 13(10). MDPI
Viruses, Vol 13, Iss 2067, p 2067 (2021)
Viruses, 13(10):2067. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 13
Issue 10

HIV is an independent risk factor of cardiovascular disease (CVD)
therefore, perinatally HIV-infected (PHIV) children potentially have a greater CVD risk at older age. Lipoprotein(a) (Lp(a)) is an established risk factor for CVD in the general p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f2db1acfa71d0e3660c8ac029336e7
http://www.scopus.com/inward/record.url?scp=85117343876&partnerID=8YFLogxK

Zobrazit plný text záznamu

Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease

Autor: Jeannette Hübener-Schmid, Jiri Klima, Sonay Keskin, Huu Phuc Nguyen, Pavlina Konstantinova, Janice Stricker-Shaver, Eva Haas, Marina Sogorb-Gonzalez, Stefan Juhas, Lodewijk J.A. Toonen, Melvin M. Evers, Jana Juhasova, Sander J. H. van Deventer, Zdenka Ellederova, Jan Motlik, Raygene Martier

Publikováno v: Molecular Therapy: Methods & Clinical Development, Vol 15, Iss, Pp 343-358 (2019)
Molecular Therapy. Methods & Clinical Development

Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is a progressiveneurodegenerative disorder caused by a CAG expansion in the ATXN3 gene. The expanded CAGrepeat is translated into a prolonged polyglutamine repeat in the ataxin-3 pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35dc5318c93404e9635a237e3ec3a951
http://www.sciencedirect.com/science/article/pii/S2329050119301160

Zobrazit plný text záznamu

Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease

Autor: Cynthia Brouwers, Pavlina Konstantinova, Amber L. Southwell, Hailey Findlay Black, Michael R. Hayden, Lisa M. Anderson, Nicholas S. Caron, Melvin M. Evers, Xiang Zhu, Seunghyun Ko, Louisa Dal Cengio, Yuanyun Xie, Sander J. H. van Deventer

Publikováno v: Nucleic Acids Research

Huntington disease (HD) is a fatal neurodegenerative disease caused by a pathogenic expansion of a CAG repeat in the huntingtin (HTT) gene. There are no disease-modifying therapies for HD. Artificial microRNAs targeting HTT transcripts for degradatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4726139682b402c98fa822b51aaaf5d5
http://europepmc.org/articles/PMC7145682

Zobrazit plný text záznamu

Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs

Autor: Christian F. Meyer, Bart A. Nijmeijer, Valerie Ferreira, Martin de Haan, Margit H. Lampen, Anna Majowicz, Marco Tangelder, Lisa Spronck, Harald Petry, Sander J. H. van Deventer

Publikováno v: Molecular Therapy. Methods & Clinical Development

Currently, individuals with pre-existing neutralizing antibodies (NABs) against adeno-associated virus (AAV) above titer of 5 are excluded from systemic AAV-based clinical trials. In this study we explored the impact of pre-existing anti-AAV5 NABs on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b473ab29a9d676eabe47a96eb30bf7
https://doi.org/10.1016/j.omtm.2019.05.009

Zobrazit plný text záznamu

AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes

Autor: Astrid Vallès, Sander J. H. van Deventer, Cynthia Brouwers, Marina Sogorb-Gonzalez, Raygene Martier, Sonay Keskin, Melvin M. Evers, Pavlina Konstantinova, Josse A. Depla

Publikováno v: Molecular therapy. Methods & clinical development, 15, 275-284. Nature Publishing Group
Molecular Therapy-Methods and Clinical Development, 15, 275-284. CELL PRESS
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss, Pp 275-284 (2019)

Huntington disease (HD) is a fatal neurodegenerative genetic disorder, thought to reflect a toxic gain of function in huntingtin (Htt) protein. Adeno-associated viral vector serotype 5 (AAV5)- microRNA targeting huntingtin (miHTT) is a HD gene-therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e52587067d908691c8a40a13c635bd1
https://doi.org/10.1016/j.omtm.2019.09.010

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání